Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
2.040
-0.040 (-1.92%)
At close: Apr 10, 2026, 4:00 PM EDT
2.070
+0.030 (1.47%)
After-hours: Apr 10, 2026, 7:10 PM EDT
Neumora Therapeutics Employees
Neumora Therapeutics had 96 employees as of December 31, 2025. The number of employees decreased by 14 or -12.73% compared to the previous year.
Employees
96
Change
-14
Growth
-12.73%
Revenue / Employee
n/a
Profits / Employee
-$2,468,000
Market Cap
371.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 96 | -14 | -12.73% |
| Sep 30, 2025 | 95 | -14 | -12.84% |
| Jun 30, 2025 | 96 | -12 | -11.11% |
| Mar 31, 2025 | 103 | -17 | -14.17% |
| Dec 31, 2024 | 110 | -14 | -11.29% |
| Sep 30, 2024 | 109 | -1 | -0.91% |
| Jun 30, 2024 | 108 | -2 | -1.82% |
| Mar 31, 2024 | 120 | 12 | 11.11% |
| Dec 31, 2023 | 124 | 30 | 31.91% |
| Jun 30, 2023 | 110 | 16 | 17.02% |
| Mar 31, 2023 | 108 | 14 | 14.89% |
| Dec 31, 2022 | 94 | 6 | 6.82% |
| Mar 31, 2022 | 94 | 41 | 77.36% |
| Dec 31, 2021 | 88 | 35 | 66.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Puma Biotechnology | 179 |
| Lineage Cell Therapeutics | 77 |
| Rezolute | 75 |
| PureTech Health | 56 |
| X4 Pharmaceuticals | 45 |
| Climb Bio | 29 |
| Opus Genetics | 28 |
NMRA News
- 5 days ago - Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 9 days ago - NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 12 days ago - Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 26 days ago - Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026 - GlobeNewsWire
- 7 weeks ago - Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment - Benzinga
- 2 months ago - Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 3 months ago - Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - GlobeNewsWire
- 3 months ago - Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation - GlobeNewsWire